Four precisely designed HLA-A*02:01-restricted peptides from HPV16 E6/E7 oncoproteins induced potent cytotoxic T cell responses against tumor cells in both human cell assays and transgenic mice.
4 peptides validatedComputationally predicted peptides confirmed to bind HLA-A2, activate dendritic cells, and trigger anti-tumor killer T cells
What the researchers found
Four high-affinity HLA-A*02:01-restricted peptides from HPV16 E6/E7 induced dendritic cell maturation, CD8+ T cell activation and proliferation, and potent antigen-specific cytotoxic T cell responses against tumor cells.
Why it matters
HPV causes nearly all cervical cancers and many other cancers. A therapeutic peptide vaccine that can activate the immune system to clear existing HPV infections could prevent cancer progression in millions of already-infected women.
How the study worked
Integrated immunoinformatic screening (3 T-cell epitope prediction programs, 5 bioinformatic databases), T2 cell-binding validation, ex vivo CTL induction, and in vivo immunogenicity testing in HLA-A*02:01/H-2Dd transgenic mice.
What this study cannot tell us
Restricted to HLA-A*02:01 (about half the population). Tested in transgenic mice, not yet in human clinical trials. Efficacy against established tumors in humans may differ from preclinical models. Single HPV type (HPV16) targeted.
How to read the evidence
Preclinical study with thorough multi-step validation (computational prediction, binding assays, ex vivo CTL induction, transgenic mouse immunogenicity). Strong preclinical evidence needing clinical translation.
When this study was published
Published in 2025, using state-of-the-art immunoinformatic tools for peptide vaccine design.
The bigger picture
While prophylactic HPV vaccines prevent new infections, they don't help the hundreds of millions already infected. Therapeutic peptide vaccines targeting viral oncoproteins could fill this gap and represent a broader platform for cancer immunotherapy.
Questions still open
- Can this vaccine design be expanded to cover other HLA types and HPV strains?
- How will the vaccine perform in human clinical trials against established HPV-driven lesions?
- Could this peptide-screening platform accelerate vaccine development for other virus-associated cancers?
Common questions
How is this different from the HPV vaccine I already got?
Why use peptides for a cancer vaccine?
Read the original research
Precision design of an HLA-I-targeted multiepitope vaccine against human papillomavirus 16 oncoproteins E6/E7: integrated immunoinformatic and immunogenicity profiling.
Anti-cancer drugs, 37(1), 58-66
Citation
Dai, Jie; Yang, Rui; Cun, Yina; Zhang, Xinwen; Li, Jing; Shi, Lei; Zhou, Lili; Tao, Yufen; Shi, Li; Yao, Yufeng; Liu, Shuyuan. (2026). Precision design of an HLA-I-targeted multiepitope vaccine against human papillomavirus 16 oncoproteins E6/E7: integrated immunoinformatic and immunogenicity profiling.. Anti-cancer drugs, 37(1), 58-66. https://doi.org/10.1097/CAD.0000000000001790